Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013.
On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries.
D000293:Adolescent; D026683:Advisory Committees; D002648:Child; D002675:Child, Preschool; D004672:Encephalitis, Japanese / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D022321:Japanese Encephalitis Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D014195:Travel; D014481:United States / Q000453:epidemiology; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use
D022321:Japanese Encephalitis Vaccines; D015164:Vaccines, Inactivated